uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden
Umea Univ, Dept Publ Hlth & Clin Med, Sundsvall, Sweden..
Umea Univ, Dept Publ Hlth & Clin Med, Sundsvall, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center.
Lund Univ, Dept Coagulat Disorders, Malmo, Sweden..
Show others and affiliations
2015 (English)In: Thrombosis Research, ISSN 0049-3848, E-ISSN 1879-2472, Vol. 136, no 2, 216-220 p.Article in journal (Refereed) PublishedText
Abstract [en]

Background: Warfarin treatment in Sweden holds a high standard with time in therapeutic range (TTR) over 75%. Internationally, specialized anticoagulation clinics (ACC) have shown higher TTR compared to primary health care centres (PHCC). Objectives: To compare warfarin treatment quality in Sweden for ACC versus PHCC, thereby clarifying whether centralization is for the better. Patients/methods: In total 77.058 patients corresponding to 217.058 treatment years with warfarin in the Swedish national quality register AuriculA from 1. Jan 2006 to 31. Dec 2011. Information regarding TTR was calculated from AuriculA, while patient characteristics and complications were retrieved from the Swedish National Patient Register. Results: Of the 100.554 treatment periods examined, 78.7% were monitored at ACC. Mean TTR for INR 2-3 for all patients irrespective of intended target range was 76.5% with an annual risk of bleeding or thrombotic events of 2.24% and 2.66%, respectively. TTR was significantly higher in PHCC compared to ACC (79.6% vs. 75.7%, p < 0.001), with no significant difference in overall risk of complications. Treatment periods for atrial fibrillation, except intended direct current conversion, showed similar results between ACC and PHCC without significant difference in annual risk of bleeding (2.50% vs. 2.51%) or thrombosis (3.09% vs. 3.16%). After propensity score matching there was still no significant difference in complication risk found. Conclusions: Warfarin treatment quality is consistently high in both ACC and PHCC when monitored through AuriculA in Sweden, both measured as TTR and as risk of complications. In this setting, centralized warfarin monitoring is not likely to improve the results.

Place, publisher, year, edition, pages
2015. Vol. 136, no 2, 216-220 p.
Keyword [en]
anticoagulation, primary care, anticoagulation clinic, warfarin, TTR, complications
National Category
Cardiac and Cardiovascular Systems Hematology
URN: urn:nbn:se:uu:diva-268719DOI: 10.1016/j.thromres.2015.04.016ISI: 000363953000008PubMedID: 25935649OAI: oai:DiVA.org:uu-268719DiVA: diva2:878781
Available from: 2015-12-09 Created: 2015-12-09 Last updated: 2015-12-09Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Renlund, Henrik
By organisation
UCR-Uppsala Clinical Research Center
In the same journal
Thrombosis Research
Cardiac and Cardiovascular SystemsHematology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 79 hits
ReferencesLink to record
Permanent link

Direct link